Pfizer’s Marstacimab Wins In Phase III, But Caution On Market Position, Clotting Remain

The drug showed efficacy in hemophilia A and B with no sign of clots, an issue that historically has dogged anticoagulation agents, but it remains unclear whether that advantage will hold.

Pfizer announced Phase III results for marstacimab in hemophilia • Source: Shutterstock

Pfizer Inc. posted successful topline results from the Phase III BASIS study of marstacimab in hemophilia A and B, but it remains unclear how competitive it will be on the market once approved, particularly in hemophilia A, where Sanofi’s Altuviiio (efanesoctocog alfa) won US Food and Drug Administration approval just months ago and Roche Holding AG’s Hemlibra (emicizumab) has dominated since its approval in 2017.

While one analyst was cautiously optimistic about the lack of clotting events – historically an issue with drugs that target...